Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial.

Shickh S, Clausen M, Mighton C, Gutierrez Salazar M, Zakoor KR, Kodida R, Reble E, Elser C, Eisen A, Panchal S, Aronson M, Graham T, Armel SR, Morel CF, Fattouh R, Glogowski E, Schrader KA, Hamilton JG, Offit K, Robson M, Carroll JC, Isaranuwatchai W, Kim RH, Lerner-Ellis J, Thorpe KE, Laupacis A, Bombard Y; Incidental Genomics Study Team.

BMJ Open. 2019 Oct 7;9(10):e031092. doi: 10.1136/bmjopen-2019-031092.

2.

Development of patient "profiles" to tailor counseling for incidental genomic sequencing results.

Mighton C, Carlsson L, Clausen M, Casalino S, Shickh S, McCuaig L, Joshi E, Panchal S, Graham T, Aronson M, Piccinin C, Winter-Paquette L, Semotiuk K, Lorentz J, Mancuso T, Ott K, Silberman Y, Elser C, Eisen A, Kim RH, Lerner-Ellis J, Carroll JC, Glogowski E, Schrader K, Bombard Y; Incidental Genomics Study Team.

Eur J Hum Genet. 2019 Jul;27(7):1008-1017. doi: 10.1038/s41431-019-0352-2. Epub 2019 Mar 8.

PMID:
30846854
3.

The Genomics ADvISER: development and usability testing of a decision aid for the selection of incidental sequencing results.

Bombard Y, Clausen M, Mighton C, Carlsson L, Casalino S, Glogowski E, Schrader K, Evans M, Scheer A, Baxter N, Hamilton JG, Lerner-Ellis J, Offit K, Robson M, Laupacis A.

Eur J Hum Genet. 2018 Jul;26(7):984-995. doi: 10.1038/s41431-018-0144-0. Epub 2018 Apr 27.

4.

Evaluation of a decision aid for incidental genomic results, the Genomics ADvISER: protocol for a mixed methods randomised controlled trial.

Shickh S, Clausen M, Mighton C, Casalino S, Joshi E, Glogowski E, Schrader KA, Scheer A, Elser C, Panchal S, Eisen A, Graham T, Aronson M, Semotiuk KM, Winter-Paquette L, Evans M, Lerner-Ellis J, Carroll JC, Hamilton JG, Offit K, Robson M, Thorpe KE, Laupacis A, Bombard Y.

BMJ Open. 2018 Apr 26;8(4):e021876. doi: 10.1136/bmjopen-2018-021876.

5.

Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.

Kopp RP, Stratton KL, Glogowski E, Schrader KA, Rau-Murthy R, Russo P, Coleman JA, Offit K.

Cancer. 2017 Jul 1;123(13):2452-2458. doi: 10.1002/cncr.30605. Epub 2017 Feb 7.

6.

Educational and Psychosocial Support Needs in Lynch Syndrome: Implementation and Assessment of an Educational Workshop and Support Group.

Corines MJ, Hamilton JG, Glogowski E, Anrig CA, Goldberg R, Niehaus K, Salo-Mullen E, Harlan M, Sheehan MR, Trottier M, Ahsraf A, Tran C, Jacobs L, Rau-Murthy R, Lincoln AG, Robson ME, Guillem JG, Markowitz AJ, Offit K, Stadler ZK.

J Genet Couns. 2017 Apr;26(2):232-243. doi: 10.1007/s10897-016-0015-1. Epub 2016 Oct 12.

7.

"I Don't Want to Be an Ostrich": Managing Mothers' Uncertainty during BRCA1/2 Genetic Counseling.

Fisher CL, Roccotagliata T, Rising CJ, Kissane DW, Glogowski EA, Bylund CL.

J Genet Couns. 2017 Jun;26(3):455-468. doi: 10.1007/s10897-016-9998-x. Epub 2016 Jul 30.

PMID:
27473644
8.

Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes.

Stratton KL, Alanee S, Glogowski EA, Schrader KA, Rau-Murthy R, Klein R, Russo P, Coleman J, Offit K.

Urol Oncol. 2016 May;34(5):238.e1-7. doi: 10.1016/j.urolonc.2015.11.021. Epub 2015 Dec 23.

9.

Encapsulated liquid sorbents for carbon dioxide capture.

Vericella JJ, Baker SE, Stolaroff JK, Duoss EB, Hardin JO 4th, Lewicki J, Glogowski E, Floyd WC, Valdez CA, Smith WL, Satcher JH Jr, Bourcier WL, Spadaccini CM, Lewis JA, Aines RD.

Nat Commun. 2015 Feb 5;6:6124. doi: 10.1038/ncomms7124.

PMID:
25652243
10.

Preliminary validation of a consumer-oriented colorectal cancer risk assessment tool compatible with the US Surgeon General's My Family Health Portrait.

Feero WG, Facio FM, Glogowski EA, Hampel HL, Stopfer JE, Eidem H, Pizzino AM, Barton DK, Biesecker LG.

Genet Med. 2015 Sep;17(9):753-6. doi: 10.1038/gim.2014.179. Epub 2014 Dec 18.

11.

Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families.

Arnold AG, Otegbeye E, Fleischut MH, Glogowski EA, Siegel B, Boyar SR, Salo-Mullen E, Amoroso K, Sheehan M, Berliner JL, Stadler ZK, Kauff ND, Offit K, Robson ME, Zhang L.

Breast Cancer Res Treat. 2014 Jun;145(3):625-34. doi: 10.1007/s10549-014-2987-6. Epub 2014 May 14.

PMID:
24825132
12.

Talking about familial breast cancer risk: topics and strategies to enhance mother-daughter interactions.

Fisher CL, Maloney E, Glogowski E, Hurley K, Edgerson S, Lichtenthal WG, Kissane D, Bylund C.

Qual Health Res. 2014 Apr;24(4):517-35. doi: 10.1177/1049732314524638. Epub 2014 Mar 14.

PMID:
24633365
13.

Clinical features and management of BRCA1 and BRCA2-associated prostate cancer.

Alanee SR, Glogowski EA, Schrader KA, Eastham JA, Offit K.

Front Biosci (Elite Ed). 2014 Jan 1;6:15-30. Review.

PMID:
24389137
14.

Self-assembly of gold nanoparticles on gallium droplets: controlling charge transport through microscopic devices.

Du K, Glogowski E, Tuominen MT, Emrick T, Russell TP, Dinsmore AD.

Langmuir. 2013 Nov 5;29(44):13640-6. doi: 10.1021/la403263z. Epub 2013 Oct 25.

PMID:
24102520
15.

Clinical correlation and molecular evaluation confirm that the MLH1 p.Arg182Gly (c.544A>G) mutation is pathogenic and causes Lynch syndrome.

Farrell MP, Hughes DJ, Berry IR, Gallagher DJ, Glogowski EA, Payne SJ, Kennedy MJ, Clarke RM, White SA, Muldoon CB, Macdonald F, Rehal P, Crompton D, Roring S, Duke ST, McDevitt T, Barton DE, Hodgson SV, Green AJ, Daly PA.

Fam Cancer. 2012 Sep;11(3):509-18. doi: 10.1007/s10689-012-9544-4. Review.

PMID:
22773173
16.

Sources of uncertainty about daughters' breast cancer risk that emerge during genetic counseling consultations.

Bylund CL, Fisher CL, Brashers D, Edgerson S, Glogowski EA, Boyar SR, Kemel Y, Spencer S, Kissane D.

J Genet Couns. 2012 Apr;21(2):292-304. doi: 10.1007/s10897-011-9400-y. Epub 2011 Aug 11.

PMID:
21833819
17.

Prospective immunohistochemical analysis of primary colorectal cancers for loss of mismatch repair protein expression.

Lee-Kong SA, Markowitz AJ, Glogowski E, Papadopoulos C, Stadler Z, Weiser MR, Temple LK, Guillem JG.

Clin Colorectal Cancer. 2010 Oct;9(4):255-9. doi: 10.3816/CCC.2010.n.038.

PMID:
20920999
18.

Adsorption energy of nano- and microparticles at liquid-liquid interfaces.

Du K, Glogowski E, Emrick T, Russell TP, Dinsmore AD.

Langmuir. 2010 Aug 3;26(15):12518-22. doi: 10.1021/la100497h.

PMID:
20593775
19.

Self-assembled electrical contact to nanoparticles using metallic droplets.

Du K, Knutson CR, Glogowski E, McCarthy KD, Shenhar R, Rotello VM, Tuominen MT, Emrick T, Russell TP, Dinsmore AD.

Small. 2009 Sep;5(17):1974-7. doi: 10.1002/smll.200900203. No abstract available.

PMID:
19466708
20.

Thin Film Instabilities in Blends under Cylindrical Confinement.

Chen D, Chen JT, Glogowski E, Emrick T, Russell TP.

Macromol Rapid Commun. 2009 Feb 18;30(4-5):377-83. doi: 10.1002/marc.200800730. Epub 2009 Jan 7.

PMID:
21706613
21.

Single-amplicon MSH2 A636P mutation testing in Ashkenazi Jewish patients with colorectal cancer: role in presurgical management.

Guillem JG, Glogowski E, Moore HG, Nafa K, Markowitz AJ, Shia J, Offit K, Ellis NA.

Ann Surg. 2007 Apr;245(4):560-5.

22.

Microcapsules of PEGylated gold nanoparticles prepared by fluid-fluid interfacial assembly.

Glogowski E, Tangirala R, He J, Russell TP, Emrick T.

Nano Lett. 2007 Feb;7(2):389-93. Epub 2007 Jan 26.

PMID:
17256916
23.

Increased frequency of disease-causing MYH mutations in colon cancer families.

Peterlongo P, Mitra N, Sanchez de Abajo A, de la Hoya M, Bassi C, Bertario L, Radice P, Glogowski E, Nafa K, Caldes T, Offit K, Ellis NA.

Carcinogenesis. 2006 Nov;27(11):2243-9. Epub 2006 Jun 14.

PMID:
16774938
24.

Mixed monolayer coverage on gold nanoparticles for interfacial stabilization of immiscible fluids.

Glogowski E, He J, Russell TP, Emrick T.

Chem Commun (Camb). 2005 Aug 28;(32):4050-2. Epub 2005 Jul 12.

PMID:
16091796
25.

A636P testing in Ashkenazi Jews.

Guillem JG, Moore HG, Palmer C, Glogowski E, Finch R, Nafa K, Markowitz AJ, Offit K, Ellis NA.

Fam Cancer. 2004;3(3-4):223-7. Review.

PMID:
15516845
26.

Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia.

Robson ME, Glogowski E, Sommer G, Antonescu CR, Nafa K, Maki RG, Ellis N, Besmer P, Brennan M, Offit K.

Clin Cancer Res. 2004 Feb 15;10(4):1250-4.

27.

MSH6 germline mutations are rare in colorectal cancer families.

Peterlongo P, Nafa K, Lerman GS, Glogowski E, Shia J, Ye TZ, Markowitz AJ, Guillem JG, Kolachana P, Boyd JA, Offit K, Ellis NA.

Int J Cancer. 2003 Nov 20;107(4):571-9.

28.

A636P is associated with early-onset colon cancer in Ashkenazi Jews.

Guillem JG, Rapaport BS, Kirchhoff T, Kolachana P, Nafa K, Glogowski E, Finch R, Huang H, Foulkes WD, Markowitz A, Ellis NA, Offit K.

J Am Coll Surg. 2003 Feb;196(2):222-5.

PMID:
12595050
29.

Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations.

Kauff ND, Scheuer L, Robson ME, Glogowski E, Kelly B, Barakat R, Heerdt A, Borgen PI, Davis JG, Offit K.

Genet Med. 2001 Nov-Dec;3(6):422-5.

PMID:
11715007
30.

High glucose alters the response of mesangial cell protein kinase C isoforms to endothelin-1.

Glogowski EA, Tsiani E, Zhou X, Fantus IG, Whiteside C.

Kidney Int. 1999 Feb;55(2):486-99.

31.

High glucose-induced mesangial cell altered contractility: role of the polyol pathway.

Derylo B, Babazono T, Glogowski E, Kapor-Drezgic J, Hohman T, Whiteside C.

Diabetologia. 1998 May;41(5):507-15.

PMID:
9628266

Supplemental Content

Loading ...
Support Center